44 related articles for article (PubMed ID: 38547184)
1. Identification of Optimal Parameters for Assessing Lymph Node Status of Patients with Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemoradiotherapy.
Huang X; Jiang D; Jian Z; Zeng Z; Zhang S; Fan H; Sun T; Tang H; Hou Y; Tan L
Ann Surg Oncol; 2024 Feb; 31(2):883-891. PubMed ID: 38038788
[TBL] [Abstract][Full Text] [Related]
2. ASO Author Reflections: Exploring the Best Parameter for Lymph Node Assessment in Patients with Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemoradiotherapy.
Huang X; Tan L
Ann Surg Oncol; 2024 Feb; 31(2):899-900. PubMed ID: 38006528
[No Abstract] [Full Text] [Related]
3. The patterns and risk factors of relapse in oesophageal squamous cell cancers who achieve pathologic complete response to neoadjuvant chemoradiotherapy.
Zhong J; Fang S; Chen R; Yuan J; Xie X; Lin T; Liu M; Liu Q; Fu J
Eur J Cardiothorac Surg; 2024 May; ():. PubMed ID: 38810125
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes and prognostic factors of concurrent chemoradiotherapy for anal squamous cell carcinoma in Japan.
Takahashi R; Osumi H; Wakatsuki T; Yamamoto N; Taguchi S; Nakayama I; Ooki A; Ogura M; Takahari D; Chin K; Yamaguchi K; Shinozaki E
Int J Clin Oncol; 2024 May; ():. PubMed ID: 38819609
[TBL] [Abstract][Full Text] [Related]
5. The Expression of TP63 as a Biomarker of Early Recurrence in Resected Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemoradiotherapy.
Lin CH; Cheng PL; Chuang CY; Kang YT; Lee LW; Hsiao TH; Hsu CP
Biomedicines; 2024 May; 12(5):. PubMed ID: 38791062
[TBL] [Abstract][Full Text] [Related]
6. Does cervical lymph node recurrence after oesophagectomy or definitive chemoradiotherapy for thoracic oesophageal squamous cell carcinoma benefit from salvage treatment?
Yuan X; Lv J; Dong H; Wang J
Interact Cardiovasc Thorac Surg; 2017 May; 24(5):792-795. PubMed ID: 28453803
[TBL] [Abstract][Full Text] [Related]
7. Lymph node volume predicts survival in esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy and surgery.
Pao TH; Chen YY; Chang WL; Wu SY; Lai WW; Tseng YL; Chung TJ; Lin FC
PLoS One; 2024; 19(3):e0300173. PubMed ID: 38547184
[TBL] [Abstract][Full Text] [Related]
8. Do We Need to Add Postoperative Radiotherapy in Patients Undergoing Trimodality Therapy for Esophageal Squamous Cell Carcinoma with Positive Lymph Nodes Disease?
Huang PM; Hsu FM; Lin CC; Hsu CH; Cheng JC; Lee JM
Dig Surg; 2018; 35(2):104-110. PubMed ID: 28675905
[TBL] [Abstract][Full Text] [Related]
9. Comparison of neoadjuvant chemotherapy versus upfront surgery with or without chemotherapy for patients with clinical stage III esophageal squamous cell carcinoma.
Matsuda S; Tsubosa Y; Sato H; Takebayashi K; Kawamorita K; Mori K; Niihara M; Tsushima T; Yokota T; Onozawa Y; Yasui H; Takeuchi H; Kitagawa Y
Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 26919154
[TBL] [Abstract][Full Text] [Related]
10. Supraclavicular and/or celiac lymph node metastases from thoracic esophageal squamous cell carcinoma did not compromise survival following neoadjuvant chemoradiotherapy and surgery.
Cho WK; Oh D; Ahn YC; Shim YM; Zo JI; Sun JM; Ahn MJ; Park K
Oncotarget; 2017 Jan; 8(2):3542-3552. PubMed ID: 27682879
[TBL] [Abstract][Full Text] [Related]
11. Prognostic histological factors in patients with esophageal squamous cell carcinoma after preoperative chemoradiation followed by surgery.
Tu CC; Hsu PK; Chien LI; Liu WC; Huang CS; Hsieh CC; Hsu HS; Wu YC
BMC Cancer; 2017 Jan; 17(1):62. PubMed ID: 28103913
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of positive lymph node regression grade to neoadjuvant chemoradiation for esophageal squamous cell carcinoma.
Yehan Z; Ying L; Peng G; Zongyao H; Chengmin Z; Hong Y; Sheng Q; Jie Z; Yi W; Xuefeng L; Wenwu H; Qifeng W; Yang L
J Surg Oncol; 2024 Mar; 129(4):708-717. PubMed ID: 38124398
[TBL] [Abstract][Full Text] [Related]
13. Patterns and timing of recurrence in esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiotherapy plus esophagectomy.
Nagaki Y; Motoyama S; Sato Y; Wakita A; Fujita H; Sasaki Y; Imai K; Minamiya Y
BMC Cancer; 2021 Nov; 21(1):1192. PubMed ID: 34753448
[TBL] [Abstract][Full Text] [Related]
14. Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial.
Eyck BM; van Lanschot JJB; Hulshof MCCM; van der Wilk BJ; Shapiro J; van Hagen P; van Berge Henegouwen MI; Wijnhoven BPL; van Laarhoven HWM; Nieuwenhuijzen GAP; Hospers GAP; Bonenkamp JJ; Cuesta MA; Blaisse RJB; Busch OR; Creemers GM; Punt CJA; Plukker JTM; Verheul HMW; Spillenaar Bilgen EJ; van der Sangen MJC; Rozema T; Ten Kate FJW; Beukema JC; Piet AHM; van Rij CM; Reinders JG; Tilanus HW; Steyerberg EW; van der Gaast A;
J Clin Oncol; 2021 Jun; 39(18):1995-2004. PubMed ID: 33891478
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
